Claims
- 1. A method of treating patients in need of treatment for a cardiac disorder, comprising administering to said patient a seven carbon fatty acid compound or derivative thereof, wherein said compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes.
- 2. The method of claim 1, wherein said seven carbon fatty acid compound comprises n-heptanoic acid.
- 3. The method of claim 1, wherein said seven carbon fatty acid compound comprises a triglyceride comprising n-heptanoic acid.
- 4. The method of claim 1, wherein said triglyceride comprises triheptanoin.
- 5. The method of claim 1, wherein said derivative is a five carbon fatty acid chain.
- 6. The method of claim 1, wherein said derivative is selected from the group consisting of 4-methylhexanoate, 4-methylhexenoate, 3-hydroxy-4-methylhexanoate, 5-methylhexanoate, 5-methylhexenoate and 3-hydroxy-5-methylhexanoate.
- 7. The method of claim 1, wherein said compound or derivative thereof is capable of being broken down by normal β-oxidation in humans to methylbutyric acid.
- 8. The method of claim 1, wherein said compound or derivative thereof is capable of being broken down by normal β-oxidation in humans to isovaleric acid.
- 9. The method of claim 1, wherein said compound or derivative is capable of being broken down by normal β-oxidation in humans to n-valeryl-CoA.
- 10. The method of claim 1, wherein said compound or derivative is capable of being broken down by normal β-oxidation in humans to propionyl-CoA in one or more oxidative procedures.
- 11. The method of claim 1, wherein said compound or derivative thereof is provided to said patient in an amount comprising at least about 25% of the dietary caloric requirement for said patient.
- 12. The method of claim 1, wherein said compound or derivative is provided orally.
- 13. The method of claim 1, wherein said compound or derivative is provided parenterally.
- 14. The method of claim 1, wherein said compound or derivative is provided intraperitoneally.
- 15. The method of any of claims 1-14, wherein said cardiac disorder is cardiac myopathy.
- 16. The method of any of claims 1-14, wherein said cardiac disorder is the aftermath of heart surgery and said compound or derivative is utilized for direct fueling of heart muscle.
- 17. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients comprising a seven-carbon fatty acid chain, wherein said seven-carbon fatty acid chain is characterized by the ability to transverse the inner mitochondrial membrane by a transport mechanism which does not require carnitine palmitoyltransferase I, carnitine palmitoyltransferase II, or camitine/acylcarnitine translocase and the ability to undergo mitochondrial β-oxidation, and wherein said compound is selected from the group consisting of n-heptanoic acid or a derivative thereof, a triglyceride comprising n-heptanoic acid or a derivative thereof, and triheptanoin or a derivative thereof.
- 18. A dietary formulation suitable for treatment of heart tissue in cardiac or surgical patients comprising a seven carbon fatty acid compound or derivative thereof, wherein said compound or derivative thereof is able to readily enter the mitochondrion without special transport enzymes.
- 19. The dietary formulation of claim 18, wherein said seven carbon fatty acid compound comprises n-heptanoic acid.
- 20. The dietary formulation of claim 18, wherein said seven carbon fatty acid compound comprises a triglyceride comprising n-heptanoic acid.
- 21. The dietary formulation of claim 18, wherein said triglyceride comprises triheptanoin.
- 22. The dietary formulation of claim 18, wherein said derivative is a five carbon fatty acid chain.
- 23. The dietary formulation of claim 18, wherein said derivative is selected from the group consisting of 4-methylhexanoate, 4-methylhexenoate, 3-hydroxy-4-methylhexanoate, 5-methylhexanoate, 5-methylhexenoate and 3-hydroxy-5-methylhexanoate.
- 24. The dietary formulation of claim 18, wherein said compound or derivative thereof is capable of being broken down by normal β-oxidation in humans to methylbutyric acid.
- 25. The dietary formulation of claim 18, wherein said compound or derivative thereof is capable of being broken down by normal β-oxidation in humans to isovaleric acid.
- 26. The dietary formulation of claim 18, wherein said compound or derivative is capable of being broken down by normal β-oxidation in humans to n-valeryl-CoA.
- 27. The dietary formulation of claim 18, wherein said compound or derivative is capable of being broken down by normal β-oxidation in humans to propionyl-CoA in one or more oxidative procedures.
CROSS REFERENCES TO RELATED APPLICATIONS
[0001] This application is a divisional of copending U.S. Application No. 09/890,559 filed on 03 Feb. 2000 which claims the benefit of U.S. Provisional Application No. 60/119, 038 which was filed on 05 Feb. 1999.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09890559 |
Aug 2001 |
US |
Child |
10371685 |
Feb 2003 |
US |